Cargando…

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice

Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wan, Tsuchiya, Kaoru, Kurosaki, Masayuki, Yasui, Yutaka, Inada, Kento, Kirino, Sakura, Yamashita, Koji, Sekiguchi, Shuhei, Hayakawa, Yuka, Osawa, Leona, Okada, Mao, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Kaneko, Shun, Tamaki, Nobuharu, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Asahina, Yasuhiro, Enomoto, Nobuyuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826625/
https://www.ncbi.nlm.nih.gov/pubmed/31601010
http://dx.doi.org/10.3390/cancers11101517
_version_ 1783465133452820480
author Wang, Wan
Tsuchiya, Kaoru
Kurosaki, Masayuki
Yasui, Yutaka
Inada, Kento
Kirino, Sakura
Yamashita, Koji
Sekiguchi, Shuhei
Hayakawa, Yuka
Osawa, Leona
Okada, Mao
Higuchi, Mayu
Takaura, Kenta
Maeyashiki, Chiaki
Kaneko, Shun
Tamaki, Nobuharu
Nakanishi, Hiroyuki
Itakura, Jun
Takahashi, Yuka
Asahina, Yasuhiro
Enomoto, Nobuyuki
Izumi, Namiki
author_facet Wang, Wan
Tsuchiya, Kaoru
Kurosaki, Masayuki
Yasui, Yutaka
Inada, Kento
Kirino, Sakura
Yamashita, Koji
Sekiguchi, Shuhei
Hayakawa, Yuka
Osawa, Leona
Okada, Mao
Higuchi, Mayu
Takaura, Kenta
Maeyashiki, Chiaki
Kaneko, Shun
Tamaki, Nobuharu
Nakanishi, Hiroyuki
Itakura, Jun
Takahashi, Yuka
Asahina, Yasuhiro
Enomoto, Nobuyuki
Izumi, Namiki
author_sort Wang, Wan
collection PubMed
description Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month (1M-RDI) was calculated. Results: The overall survival (OS) and progression-free survival (PFS) were 12.4 and 3.7 months. The objective response rate and disease control rate were 13.2% and 71.1%. The median total dose of regorafenib in the first month was 2080 mg (240–3360 mg), and the median 1M-RDI was 61.9% (7.1–100%). Patients with 1M-RDI ≥ 50% showed significantly longer OS and PFS than patients with 1M-RDI < 50% (HR 0.19, 95% CI 0.08–0.48, p = 0.0004 and HR 0.2, 95% CI 0.08–0.52, p = 0.0008). A 1M-RDI ≥ 50% (HR 0.18, 95% CI 0.06–0.55, p = 0.002) and hand–foot skin reaction (HR 0.03, 95% CI 0.008–0.16, p < 0.0001) were independently associated with OS. Post-regorafenib therapies were performed in 19 (86.4%) of 22 patients who had stopped regorafenib due to disease progression. Conclusion: A 1M-RDI ≥ 50% is clinically significant. Post-regorafenib therapies are commonly performed in real-world practice.
format Online
Article
Text
id pubmed-6826625
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68266252019-11-18 Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice Wang, Wan Tsuchiya, Kaoru Kurosaki, Masayuki Yasui, Yutaka Inada, Kento Kirino, Sakura Yamashita, Koji Sekiguchi, Shuhei Hayakawa, Yuka Osawa, Leona Okada, Mao Higuchi, Mayu Takaura, Kenta Maeyashiki, Chiaki Kaneko, Shun Tamaki, Nobuharu Nakanishi, Hiroyuki Itakura, Jun Takahashi, Yuka Asahina, Yasuhiro Enomoto, Nobuyuki Izumi, Namiki Cancers (Basel) Article Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month (1M-RDI) was calculated. Results: The overall survival (OS) and progression-free survival (PFS) were 12.4 and 3.7 months. The objective response rate and disease control rate were 13.2% and 71.1%. The median total dose of regorafenib in the first month was 2080 mg (240–3360 mg), and the median 1M-RDI was 61.9% (7.1–100%). Patients with 1M-RDI ≥ 50% showed significantly longer OS and PFS than patients with 1M-RDI < 50% (HR 0.19, 95% CI 0.08–0.48, p = 0.0004 and HR 0.2, 95% CI 0.08–0.52, p = 0.0008). A 1M-RDI ≥ 50% (HR 0.18, 95% CI 0.06–0.55, p = 0.002) and hand–foot skin reaction (HR 0.03, 95% CI 0.008–0.16, p < 0.0001) were independently associated with OS. Post-regorafenib therapies were performed in 19 (86.4%) of 22 patients who had stopped regorafenib due to disease progression. Conclusion: A 1M-RDI ≥ 50% is clinically significant. Post-regorafenib therapies are commonly performed in real-world practice. MDPI 2019-10-09 /pmc/articles/PMC6826625/ /pubmed/31601010 http://dx.doi.org/10.3390/cancers11101517 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wang, Wan
Tsuchiya, Kaoru
Kurosaki, Masayuki
Yasui, Yutaka
Inada, Kento
Kirino, Sakura
Yamashita, Koji
Sekiguchi, Shuhei
Hayakawa, Yuka
Osawa, Leona
Okada, Mao
Higuchi, Mayu
Takaura, Kenta
Maeyashiki, Chiaki
Kaneko, Shun
Tamaki, Nobuharu
Nakanishi, Hiroyuki
Itakura, Jun
Takahashi, Yuka
Asahina, Yasuhiro
Enomoto, Nobuyuki
Izumi, Namiki
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
title Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
title_full Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
title_fullStr Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
title_full_unstemmed Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
title_short Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
title_sort sorafenib-regorafenib sequential therapy in japanese patients with unresectable hepatocellular carcinoma—relative dose intensity and post-regorafenib therapies in real world practice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826625/
https://www.ncbi.nlm.nih.gov/pubmed/31601010
http://dx.doi.org/10.3390/cancers11101517
work_keys_str_mv AT wangwan sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT tsuchiyakaoru sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT kurosakimasayuki sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT yasuiyutaka sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT inadakento sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT kirinosakura sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT yamashitakoji sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT sekiguchishuhei sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT hayakawayuka sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT osawaleona sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT okadamao sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT higuchimayu sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT takaurakenta sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT maeyashikichiaki sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT kanekoshun sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT tamakinobuharu sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT nakanishihiroyuki sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT itakurajun sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT takahashiyuka sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT asahinayasuhiro sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT enomotonobuyuki sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice
AT izuminamiki sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice